Effectiveness of biologic therapies on psoriasis vulgaris
DOI:
https://doi.org/10.35335/midwifery.v12i1.1459Keywords:
Biologic Agents, Biologic Therapy, Psoariasis VulgarisAbstract
Psoriasis is a chronic proliferative inflammatory condition mediated by the immune system that is characterized by erythematous plaques covered by silvery scales. Psoriasis vulgaris is mediated by T lymphocytes, wherein the activation of innate immune cells and pathogenic T cells leads to inflammation of the skin and excessive growth of keratinocytes. The pathogenesis of psoriasis vulgaris has significantly enhanced comprehension of cutaneous immunology, facilitating an introduction to highly effective therapies. Biologic therapy binds to a specific cytokine such as TNF-α, IL-12, IL-17, or IL-23, unlike non-biologic therapy primarily focuses on resolving clinical manifestation without targeting the underlying causes. A literature review was performed to present the effectiveness of biologic therapies as a part of psoriasis vulgaris management.
Downloads
References
Armstrong, April, & Charlotte. (2020). Pathophysiology, Clinical Presentation, and Treatment of Psoriasis. Jama, 323(19). https://doi.org/10.1001/jama.2020.4006
Armstrong, Fahrbach, K., Leonardi, C., Augustin, M., Neupane, B., & Kazmierska, P. (2022). Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis. Dermatol Ther (Heidelb), 12(8), 1777-1792. https://doi.org/10.1007/s13555-022-00760-8
Armstrong, Mehta, M. D., Schupp, C. W., Gondo, G. C., Bell, S. J., & Griffiths, C. E. M. (2021). Psoriasis Prevalence in Adults in the United States. JAMA Dermatol, 157(8), 940-946. https://doi.org/10.1001/jamadermatol.2021.2007
Asahina, A., Okubo, Y., Morita, A., Tada, Y., Igarashi, A., Langley, R. G., Deherder, D., Matano, M., Vanvoorden, V., Wang, M., Ohtsuki, M., & Nakagawa, H. (2023). Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study. Dermatol Ther (Heidelb), 13(3), 751-768. https://doi.org/10.1007/s13555-022-00883-y
Bai, F., Li, G. G., Liu, Q., Niu, X., Li, R., & Ma, H. (2019). Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. J Immunol Res, 2019, 2546161. https://doi.org/10.1155/2019/2546161
Blauvelt, A. (2016). Safety of secukinumab in the treatment of psoriasis. Expert Opin Drug Saf, 15(10), 1413-1420. https://doi.org/10.1080/14740338.2016.1221923
Blauvelt, A., Kimball, A. B., Augustin, M., Okubo, Y., Witte, M. M., Capriles, C. R., Sontag, A., Arora, V., Osuntokun, O., & Strober, B. (2022). Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1). Br J Dermatol, 187(6), 866-877. https://doi.org/10.1111/bjd.21743
Brownstone, N. D., Hong, J., Mosca, M., Hadeler, E., Liao, W., Bhutani, T., & Koo, J. (2021). Biologic Treatments of Psoriasis: An Update for the Clinician. Biologics, 15, 39-51. https://doi.org/10.2147/BTT.S252578
Cingoz, O. (2009). Mini-Review Ustekinumab. mAbs Journal.
Craig, S., & Warren, R. B. (2020). Ixekizumab for the treatment of psoriasis: up-to-date. Expert Opin Biol Ther, 20(6), 549-557. https://doi.org/10.1080/14712598.2020.1729736
Ellis, & Azmat. (2023). Adalimumab. In StatPearls. https://www.ncbi.nlm.nih.gov/pubmed/32491812
Esposito, M., Carubbi, F., Giunta, A., Alunno, A., Giacomelli, R., & Fargnoli, M. C. (2020). Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis. Expert Rev Clin Immunol, 16(2), 119-128. https://doi.org/10.1080/1744666X.2020.1713754
Frampton, J. E. (2019). Tildrakizumab: A Review in Moderate-to-Severe Plaque Psoriasis. Am J Clin Dermatol, 20(2), 295-306. https://doi.org/10.1007/s40257-019-00435-9
Franziska Grän, A. K., Edgar Serfling, Matthias Goebeler, Khalid Muhammad. (2020). Current Developments in the Immunology of Psoriasis. Yale Journal of Biology and Medicine, 93.
Ghosh, S., Gensler, L. S., Yang, Z., Gasink, C., Chakravarty, S. D., Farahi, K., Ramachandran, P., Ott, E., & Strober, B. E. (2019). Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs. Drug Saf, 42(6), 751-768. https://doi.org/10.1007/s40264-019-00797-3
Gordon, K. B., Blauvelt, A., Papp, K. A., Langley, R. G., Luger, T., Ohtsuki, M., Reich, K., Amato, D., Ball, S. G., Braun, D. K., Cameron, G. S., Erickson, J., Konrad, R. J., Muram, T. M., Nickoloff, B. J., Osuntokun, O. O., Secrest, R. J., Zhao, F., Mallbris, L., . . . Group, U.-S. (2016). Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. N Engl J Med, 375(4), 345-356. https://doi.org/10.1056/NEJMoa1512711
Gottlieb, A. B., Deodhar, A., McInnes, I. B., Baraliakos, X., Reich, K., Schreiber, S., Bao, W., Marfo, K., Richards, H. B., Pricop, L., Shete, A., Trivedi, V., Keefe, D., Papavassilis, C. C., Jagiello, P., Papanastasiou, P., Mease, P. J., & Lebwohl, M. (2022). Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data. Acta Derm Venereol, 102, adv00698. https://doi.org/10.2340/actadv.v102.563
Griffiths, C. E., Armstrong, A. W., Gudjonsson, J. E., & Barker. (2021). Psoriasis. Lancet, 397(10281), 1301-1315. https://doi.org/10.1016/S0140-6736(20)32549-6
Ighani, A., Yu, A. M., Sandhu, V. K., Benjamin Barankin, & Manolson, M. F. (2018). Satisfaction and Awareness of Systemic Psoriasis Treatments: A National Survey Comparing Biologic and Nonbiologic Users. Journal of Cutaneous Medicine and Surgery, 1-9.
Iznardo, H., & Puig, L. (2020). The safety of brodalumab for the treatment of psoriasis. Expert Opin Drug Saf, 19(4), 365-372. https://doi.org/10.1080/14740338.2020.1730326
Koca, T. T. (2016). A short summary of clinical types of psoriasis. Northern Clinics of Istanbul. https://doi.org/10.14744/nci.2016.16023
Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., Rivas, E., Tsai, T. F., Wasel, N., Tyring, S., Salko, T., Hampele, I., Notter, M., Karpov, A., Helou, S., . . . Group, F. S. (2014). Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med, 371(4), 326-338. https://doi.org/10.1056/NEJMoa1314258
Lanna, Zangrilli, Bavetta, Campione, & Bianchi. (2020). Efficacy and safety of adalimumab in difficult-to-treat psoriasis. Dermatol Ther, 33(3), e13374. https://doi.org/10.1111/dth.13374
Lee, A., & Scott, L. J. (2020). Certolizumab Pegol: A Review in Moderate to Severe Plaque Psoriasis. BioDrugs, 34(2), 235-244. https://doi.org/10.1007/s40259-020-00416-z
Marinas, J. E., Kim, W. B., Shahbaz, A., Qiang, J. K., Greaves, S., & Yeung, J. (2018). Survival rates of biological therapies for psoriasis treatment in real-world clinical practice: A Canadian multicentre retrospective study. Australas J Dermatol, 59(1), e11-e14. https://doi.org/10.1111/ajd.12548
Menter, A., Gelfand, J. M., Connor, C., Armstrong, A. W., Cordoro, K. M., Davis, D. M. R., Elewski, B. E., Gordon, K. B., Gottlieb, A. B., Kaplan, D. H., Kavanaugh, A., Kiselica, M., Kivelevitch, D., Korman, N. J., Kroshinsky, D., Lebwohl, M., Leonardi, C. L., Lichten, J., Lim, H. W., . . . Elmets, C. A. (2020). Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol, 82(6), 1445-1486. https://doi.org/10.1016/j.jaad.2020.02.044
Menter, A., Strober, B. E., Kaplan, D. H., Kivelevitch, D., Prater, E. F., Stoff, B., Armstrong, A. W., Connor, C., Cordoro, K. M., Davis, D. M. R., Elewski, B. E., Gelfand, J. M., Gordon, K. B., Gottlieb, A. B., Kavanaugh, A., Kiselica, M., Korman, N. J., Kroshinsky, D., Lebwohl, M., . . . Elmets, C. A. (2019). Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol, 80(4), 1029-1072. https://doi.org/10.1016/j.jaad.2018.11.057
Nast, A., Smith, C., Spuls, P. I., Avila Valle, G., Bata-Csorgo, Z., Boonen, H., De Jong, E., Garcia-Doval, I., Gisondi, P., Kaur-Knudsen, D., Mahil, S., Malkonen, T., Maul, J. T., Mburu, S., Mrowietz, U., Reich, K., Remenyik, E., Ronholt, K. M., Sator, P. G., . . . Dressler, C. (2020). EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol, 34(11), 2461-2498. https://doi.org/10.1111/jdv.16915
Oliver, R., Krueger, J. G., Glatt, S., Vajjah, P., Mistry, C., Page, M., Edwards, H., Garcet, S., Li, X., Dizier, B., Maroof, A., Watling, M., El Baghdady, A., Baeten, D., Ionescu, L., & Shaw, S. (2022). Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study. Br J Dermatol, 186(4), 652-663. https://doi.org/10.1111/bjd.20827
Pan, A., & Gerriets, V. (2023). Etanercept. In StatPearls. https://www.ncbi.nlm.nih.gov/pubmed/31424836
Papp, K. A., Gniadecki, R., Beecker, J., Dutz, J., Gooderham, M. J., Hong, C. H., Kirchhof, M. G., Lynde, C. W., Maari, C., Poulin, Y., & Vender, R. B. (2021). Psoriasis Prevalence and Severity by Expert Elicitation. Dermatol Ther (Heidelb), 11(3), 1053-1064. https://doi.org/10.1007/s13555-021-00518-8
Papp, K. A., Reich, K., Paul, C., Blauvelt, A., Baran, W., Bolduc, C., Toth, D., Langley, R. G., Cather, J., Gottlieb, A. B., Thaci, D., Krueger, J. G., Russell, C. B., Milmont, C. E., Li, J., Klekotka, P. A., Kricorian, G., & Nirula, A. (2016). A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol, 175(2), 273-286. https://doi.org/10.1111/bjd.14493
Petit, R. G., Cano, A., Ortiz, A., Espina, M., Prat, J., Munoz, M., Severino, P., Souto, E. B., Garcia, M. L., Pujol, M., & Sanchez-Lopez, E. (2021). Psoriasis: From Pathogenesis to Pharmacological and Nano-Technological-Based Therapeutics. Int J Mol Sci, 22(9). https://doi.org/10.3390/ijms22094983
Reich, K., Gordon, K. B., Strober, B. E., Armstrong, A. W., Miller, M., Shen, Y. K., You, Y., Han, C., Yang, Y. W., Foley, P., & Griffiths, C. E. M. (2021). Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2. Br J Dermatol, 185(6), 1146-1159. https://doi.org/10.1111/bjd.20568
Rendon, A., & Schakel, K. (2019). Psoriasis Pathogenesis and Treatment. Int J Mol Sci, 20(6). https://doi.org/10.3390/ijms20061475
Robinson, S., Moon, T. M., Eng, T. K., Yuen, T. T., Jong, T. J., Selvarajah, L., Chiang, T. W., Chiat, T. Y., Tiong, J., Chinthapatla, H., Eng, S. K., & Thevarajah, S. (2023). Dermatology Life Quality Index in Patients with Psoriasis Treated with Biologic Versus Non-biologic Treatment in Malaysia: A Retrospective Cross-Sectional Study. Drugs Real World Outcomes, 10(2), 291-298. https://doi.org/10.1007/s40801-023-00359-1
Ruggiero, Picone, Martora, Fabbrocini, & Megna. (2022). Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence. Clin Cosmet Investig Dermatol, 15, 1649-1658. https://doi.org/10.2147/CCID.S364640
Strober, B., Menter, A., Leonardi, C., Gordon, K., Lambert, J., Puig, L., Photowala, H., Longcore, M., Zhan, T., & Foley, P. (2020). Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies. J Eur Acad Dermatol Venereol, 34(12), 2830-2838. https://doi.org/10.1111/jdv.16521
Subedi, S., Gong, Y., Chen, Y., & Shi, Y. (2019). Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events. Drug Des Devel Ther, 13, 2491-2502. https://doi.org/10.2147/DDDT.S200147
Tokuyama, M., & Mabuchi, T. (2020). New Treatment Addressing the Pathogenesis of Psoriasis. Int J Mol Sci, 21(20). https://doi.org/10.3390/ijms21207488
Wang, J., Zhan, Q., & Zhang, L. (2016). A systematic review on the efficacy and safety of Infliximab in patients with psoriasis. Hum Vaccin Immunother, 12(2), 431-437. https://doi.org/10.1080/21645515.2015.1081322
Wu, C.-L., Chang, Y.-C., Yao, W.-T., & Chiang, T.-I. (2024). Exploring the Effectiveness of Biological Therapy in Patients with Psoriasis: Body Image and Quality of Life. Medicina, 60(1). https://doi.org/10.3390/medicina60010160
Xie, F., Wang, R., Zhao, Z. G., Meng, X. F., Lin, B. W., Yang, J., Wang, W. J., Ding, X. Y., Yang, Y., Zhao, H., Li, C. X., Li, H. J., & Zhou, Y. (2017). Safety and efficacy of etanercept monotherapy for moderate-to-severe plaque psoriasis: A prospective 12-week follow-up study. J Huazhong Univ Sci Technolog Med Sci, 37(6), 943-947. https://doi.org/10.1007/s11596-017-1832-7
Yan, B.-X., Chen, X.-Y., Ye, L.-R., Chen, J.-Q., Zheng, M., & Man, X.-Y. (2021). Cutaneous and Systemic Psoriasis: Classifications and Classification for the Distinction. Frontiers in Medicine, 8. https://doi.org/10.3389/fmed.2021.649408
Yang, E. J., Beck, K. M., Sanchez, I. M., Koo, J., & Liao, W. (2018). The impact of genital psoriasis on quality of life: a systematic review. Psoriasis (Auckl), 8, 41-47. https://doi.org/10.2147/PTT.S169389
Zangrilli, Bavetta, & Bianchi. (2020). Adalimumab in children and adolescents with severe plaque psoriasis: a safety evaluation. Expert Opin Drug Saf, 19(4), 433-438. https://doi.org/10.1080/14740338.2020.1752659
